StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for CRDF yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $1.65 | $1.67 | +1.21% | 0.9M |
| 05-18 | $1.67 | $1.69 | +1.20% | 1.1M |
| 05-19 | $1.69 | $1.76 | +4.14% | 3.1M |
| 05-20 | $1.72 | $1.84 | +6.98% | 1.8M |
| 05-21 | $1.85 | $1.79 | -3.24% | 1.5M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $41.00K | $593.00K | $350.00K | $230.00K |
Operating Income | $-12.85M | $-48.96M | $-41.13M | $-29.16M |
Net Income | $-12.35M | $-45.85M | $-38.63M | $-13.94M |
EPS (Diluted) | $-0.18 | $-0.69 | $-0.58 | $-0.41 |
Total Assets | $49.17M | $61.88M | $63.78M | $75.74M |
Total Liabilities | $14.46M | $16.50M | $14.99M | $17.13M |
Cash & Equivalents | $8.54M | $17.47M | $10.13M | $10.78M |
Free Cash Flow OCF − CapEx | Not available | $-37.97M | $-32.00M | $-21.15M |
Shares Outstanding | 68.37M | 68.31M | 67.09M | 66.53M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.